Skip to main content

Phenotypic drug discovery with high content screening


Today's drug discovery strategies require candidate compounds to fail early and cheaply in the discovery stage, rather than late and expensively in the clinical phase. Testing compounds early in physiologically relevant model systems and leveraging rich information from image-based screens are ways of focusing on those compounds that give rise to the right phenotypic changes without undesirable effects on the system.


  • Why you should consider phenotypic vs. target-based drug discovery strategies
  • Challenges you should be aware of for phenotypic assays
  • How to maximize the return on your phenotypic assays

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Phenotypic drug discovery with high content screening

Download Whitepaper